Why predictive intelligence is changing the Medical Science Liaison model

Tern plc

Medical Science Liaisons have traditionally been the scientific connection between pharmaceutical companies and healthcare professionals. Their role is centred on non promotional dialogue, explaining clinical evidence, answering scientific questions and collecting feedback from the field. For many years this model relied on structured engagement plans, established opinion leaders and scheduled interactions at congresses or advisory boards.

However, the information environment surrounding modern healthcare has changed significantly. Scientific debate now develops continuously across digital platforms, academic publications and professional networks. Clinicians discuss emerging evidence faster and across more channels than before.

The challenge for Medical Affairs teams is not simply operational. Pharmaceutical companies increasingly rely on Medical Affairs to provide early visibility on shifts in clinical thinking, treatment behaviour and emerging scientific questions. If insight from the field arrives too slowly, the organisation may miss early signals that influence how therapies are positioned, studied or adopted in practice.

Traditional MSL planning typically focuses on a fixed group of recognised experts. While these relationships remain valuable, influence in healthcare conversations is now more fluid. New voices often emerge quickly around specific research topics, clinical questions or therapeutic developments. Identifying these individuals early can be important for companies seeking to understand how medical narratives are evolving.

Predictive intelligence offers a way to address this gap. By analysing large volumes of healthcare discussion, scientific publication activity and other behavioural signals, data models can identify patterns that indicate where medical conversations are forming and who is shaping them. This allows Medical Affairs teams to prioritise engagement based on current influence rather than relying solely on historical relationships.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Why predictive intelligence is changing the Medical Science Liaison model

Predictive analytics is enabling Medical Affairs teams to identify emerging clinical discussions earlier and engage the most relevant healthcare professionals.

Messaging precision becomes a commercial lever for pharma in 2026

As patent pressures mount and new therapies launch, the ability to measure message resonance is becoming central to pharma commercial strategy.

Tern Plc secures extension on £120,000 loan balance

Tern PLC has extended the repayment date of its loan facility to 11 September 2026, providing additional flexibility as it plans funding for investee companies. £120,000 plus monthly interest remains payable following a partial repayment.

Tern Plc issues 78.2m shares following Open Offer

Tern Plc announced valid acceptances for 78,163,662 Open Offer Shares at 0.40 pence per share, generating gross proceeds of about £312,654. The enlarged share capital will total 750,877,367 ordinary shares upon admission to AIM.

Fundamental XR expands access to immersive training with web-enabled platform

Its new Immersive Web platform brings immersive training into the browser, lowering adoption barriers and broadening enterprise reach.

GLP-1 receptor agonists: Strategic market shift

Rapid uptake, evolving regulation and digital integration are reshaping the investment case for metabolic health therapies.

Search